Lina Helena Lankhorst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lina Helena Lankhorst has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Olga Husson
3 shared publications- Winette T. A. van der Graaf
Netherlands Cancer Institute, Amsterdam, The Netherlands
3 shared publications - Noor A. A. Giesbertz
Department of Clinical Genetics Antoni van Leeuwenhoek Netherlands Cancer Institute Amsterdam The Netherlands
2 shared publications - Adrianus Johannes de Langen
Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
1 shared publication - Alvin Kamili
Children’s Cancer Institute Australia, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW 2052 Australia
1 shared publication - Anke van Den Berg
Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 19 September 2026
- Published by Elsevier in PEC Global
- Vol. 2
Healthcare professionals’ views on the use of whole genome sequencing for adolescents and young adults with advanced cancer
- 19 September 2026
- Published by Elsevier in PEC Global
- Vol. 2
Open AccessHealthcare professionals’ views on the use of whole genome sequencing for adolescents and young adults with advanced cancer
- Open Access
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Introducing Whole Genome Sequencing to Adolescents and Young Adults (AYA) with Poor-prognosis Cancer into Standard Oncology Care: What do they know, expect and value?
Purpose: Adolescents and young adults (AYAs; aged 18–39 years at cancer diagnosis) with poor-prognosis cancer may benefit from whole-genome sequencing (WGS) to optimise treatment selection and refine diagnosis. Given their distinct life phase, AYAs may have specific expectations, motivations, and information needs regarding WGS. This study explores AYAs' knowledge, expectations, motivations, and communication preferences prior to disclosure of WGS results.Methods: This study presents a cross-sectional analysis of baseline data from the longitudinal multicentre mixed-methods GEN-impact-AYA study, collected prior to disclosure of WGS results. Participants (N = 105) completed items assessing knowledge and expectations of WGS; factors influencing the decision to pursue WGS; attitudes toward WGS; perceived advantages and disadvantages; and satisfaction with WGS and the information provided.Results: Overall, AYAs were satisfied with their decision to have WGS. Main motivations included its potential to support treatment decisions (77.7%) and a desire to help future patients (53.4%). The majority (59.0%) had good knowledge of WGS. AYAs estimated, on average, a 60.5% probability that WGS would contribute to their diagnosis or treatment, on a scale from 0 (very unlikely) to 100% (very likely). However, many AYAs reported receiving limited information on the likelihood of treatment implications and potential germline findings.Conclusion: AYAs with poor-prognosis cancer receiving paired tumour–normal WGS recognise its potential to guide treatment decisions and contribute to future care. However, their expectations often reflect hope and may exceed the realistic clinical yield of WGS. Clinicians should clearly communicate tumour-specific implications of WGS, including potential germline findings. Given the high information-seeking behaviour among AYAs, directing them to trustworthy (online) resources before disclosure of WGS results is essential.
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntroducing Whole Genome Sequencing to Adolescents and Young Adults (AYA) with Poor-prognosis Cancer into Standard Oncology Care: What do they know, expect and value?
Purpose: Adolescents and young adults (AYAs; aged 18–39 years at cancer diagnosis) with poor-prognosis cancer may benefit from whole-genome sequencing (WGS) to optimise treatment selection and refine diagnosis. Given their distinct life phase, AYAs may have specific expectations, motivations, and information needs regarding WGS. This study explores AYAs' knowledge, expectations, motivations, and communication preferences prior to disclosure of WGS results.Methods: This study presents a cross-sectional analysis of baseline data from the longitudinal multicentre mixed-methods GEN-impact-AYA study, collected prior to disclosure of WGS results. Participants (N = 105) completed items assessing knowledge and expectations of WGS; factors influencing the decision to pursue WGS; attitudes toward WGS; perceived advantages and disadvantages; and satisfaction with WGS and the information provided.Results: Overall, AYAs were satisfied with their decision to have WGS. Main motivations included its potential to support treatment decisions (77.7%) and a desire to help future patients (53.4%). The majority (59.0%) had good knowledge of WGS. AYAs estimated, on average, a 60.5% probability that WGS would contribute to their diagnosis or treatment, on a scale from 0 (very unlikely) to 100% (very likely). However, many AYAs reported receiving limited information on the likelihood of treatment implications and potential germline findings.Conclusion: AYAs with poor-prognosis cancer receiving paired tumour–normal WGS recognise its potential to guide treatment decisions and contribute to future care. However, their expectations often reflect hope and may exceed the realistic clinical yield of WGS. Clinicians should clearly communicate tumour-specific implications of WGS, including potential germline findings. Given the high information-seeking behaviour among AYAs, directing them to trustworthy (online) resources before disclosure of WGS results is essential.
- Open Access
- 27 March 2026
- Published by BMJ in Journal of Medical Genetics
- Vol. 63 (7) , 439-446
Perspectives of adolescents and young adults with advanced cancer on complete genomic analysis in standard oncology care
Purpose Tumour genomic profiling, including whole genome sequencing (WGS), offers opportunities for refined diagnosis and personalised treatment for adolescents and young adults (AYAs) with advanced or poor prognostic cancer. This study explores AYAs’ attitudes towards receiving WGS in standard oncological care, their preferences for the communication of results and the perceived impact of these results. Methods Semistructured interviews were conducted with AYAs (aged 18–39 years at initial cancer diagnosis). Interviews were transcribed and analysed thematically using an inductive approach in NVivo (V.12). Results 16 AYAs participated. Analysis revealed five themes: (1) confidence in the current WGS procedure; (2) challenges in understanding and communicating purpose and results of WGS; (3) dual emotional impact of WGS results; (4) high value placed on hereditary information for self and loved ones and (5) balancing altruism and personal risk in genomic data sharing. Conclusion AYAs with advanced cancer generally value WGS, even when results have no immediate clinical consequences. They describe benefits such as hope, reassurance and the opportunity to help future patients. However, misunderstandings about its purpose, difficulties in interpreting genomic findings and limited awareness of potential hereditary implications may limit its optimal use. Strengthening communication with age-appropriate, accessible explanatory materials will be essential to ensure AYAs understand the purpose and potential outcomes of WGS and can fully benefit from its implementation.
- 27 March 2026
- Published by BMJ in Journal of Medical Genetics
- Vol. 63 (7) , 439-446
Open AccessPerspectives of adolescents and young adults with advanced cancer on complete genomic analysis in standard oncology care
Purpose Tumour genomic profiling, including whole genome sequencing (WGS), offers opportunities for refined diagnosis and personalised treatment for adolescents and young adults (AYAs) with advanced or poor prognostic cancer. This study explores AYAs’ attitudes towards receiving WGS in standard oncological care, their preferences for the communication of results and the perceived impact of these results. Methods Semistructured interviews were conducted with AYAs (aged 18–39 years at initial cancer diagnosis). Interviews were transcribed and analysed thematically using an inductive approach in NVivo (V.12). Results 16 AYAs participated. Analysis revealed five themes: (1) confidence in the current WGS procedure; (2) challenges in understanding and communicating purpose and results of WGS; (3) dual emotional impact of WGS results; (4) high value placed on hereditary information for self and loved ones and (5) balancing altruism and personal risk in genomic data sharing. Conclusion AYAs with advanced cancer generally value WGS, even when results have no immediate clinical consequences. They describe benefits such as hope, reassurance and the opportunity to help future patients. However, misunderstandings about its purpose, difficulties in interpreting genomic findings and limited awareness of potential hereditary implications may limit its optimal use. Strengthening communication with age-appropriate, accessible explanatory materials will be essential to ensure AYAs understand the purpose and potential outcomes of WGS and can fully benefit from its implementation.
- Open Access
- 22 September 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 140, 103021
Genomic distinctions in adolescent and young adult cancer: A comprehensive review
- 22 September 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 140, 103021
Open AccessGenomic distinctions in adolescent and young adult cancer: A comprehensive review
- Open Access
Core Patient-Centered Outcomes for Adolescents and Young Adults with Cancer: A Comprehensive Review of the Literature from the STRONG-AYA Project
Background: In adolescents and young adults (AYAs) with cancer, the importance of patient-centered research outcomes is increasingly acknowledged and there is a need for consensus on the most relevant outcomes. This review provides a comprehensive overview of outcomes relevant to AYAs with cancer in order to develop an AYA-specific core outcome set (COS) as part of the European project STRONG-AYA. Methods: A literature search was conducted to identify relevant articles in five databases. Each article was reviewed by two independent researchers, using Rayyan (an online tool) to screen articles by their title/abstract and then by their full text. Subsequently, the data were extracted using a predefined, tailored extraction framework. Results: In total, 17,301 articles were screened, of which 1631 were included in the analyses. Registry studies (52.9%) were the most used study type. Well-represented continents were North America (50.3%) and Europe (27.8%). Of the five core areas, functioning (47.0%) and epidemiology (44.9%) were covered most often, followed by physiological/clinical (42.4%), resource use (6.1%), and adverse events (4.5%). The outcome domains that were represented the most include mortality/survival (43.1%), delivery of care (23.4%), outcomes relating to neoplasms (22.7%), and emotional functioning/well-being (19.2%). Conclusions: This literature review provides a foundation for the development of an AYA-specific COS for improving the relevance and efficiency of measuring outcomes, the pooling of (international) research data, and the value of care for current and future AYAs with cancer. Finalization and refinement of the COS should be a priority for future research.
Open AccessCore Patient-Centered Outcomes for Adolescents and Young Adults with Cancer: A Comprehensive Review of the Literature from the STRONG-AYA Project
Background: In adolescents and young adults (AYAs) with cancer, the importance of patient-centered research outcomes is increasingly acknowledged and there is a need for consensus on the most relevant outcomes. This review provides a comprehensive overview of outcomes relevant to AYAs with cancer in order to develop an AYA-specific core outcome set (COS) as part of the European project STRONG-AYA. Methods: A literature search was conducted to identify relevant articles in five databases. Each article was reviewed by two independent researchers, using Rayyan (an online tool) to screen articles by their title/abstract and then by their full text. Subsequently, the data were extracted using a predefined, tailored extraction framework. Results: In total, 17,301 articles were screened, of which 1631 were included in the analyses. Registry studies (52.9%) were the most used study type. Well-represented continents were North America (50.3%) and Europe (27.8%). Of the five core areas, functioning (47.0%) and epidemiology (44.9%) were covered most often, followed by physiological/clinical (42.4%), resource use (6.1%), and adverse events (4.5%). The outcome domains that were represented the most include mortality/survival (43.1%), delivery of care (23.4%), outcomes relating to neoplasms (22.7%), and emotional functioning/well-being (19.2%). Conclusions: This literature review provides a foundation for the development of an AYA-specific COS for improving the relevance and efficiency of measuring outcomes, the pooling of (international) research data, and the value of care for current and future AYAs with cancer. Finalization and refinement of the COS should be a priority for future research.
- Open Access
- 1 June 2024
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 3
Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma
- 1 June 2024
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 3
Open AccessPreclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma
- Top Cited Papers
- 3 March 2022
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 22 (6) , 340-355
Exploiting senescence for the treatment of cancer
Senescence is a cellular response to a variety of stress signals that is characterized by a stable withdrawal from the cell cycle and major changes in cell morphology and physiology. While most research on senescence has been performed on non-cancer cells, it is evident that cancer cells can also mount a senescence response. In this Review, we discuss how senescence can be induced in cancer cells. We describe the distinctive features of senescent cancer cells and how these changes in cellular physiology might be exploited for the selective eradication of these cells (senolysis). We discuss activation of the host immune system as a particularly attractive way to clear senescent cancer cells. Finally, we consider the challenges and opportunities provided by a ‘one-two punch’ sequential treatment of cancer with pro-senescence therapy followed by senolytic therapy.
- 3 March 2022
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 22 (6) , 340-355
Top Cited PapersExploiting senescence for the treatment of cancer
Senescence is a cellular response to a variety of stress signals that is characterized by a stable withdrawal from the cell cycle and major changes in cell morphology and physiology. While most research on senescence has been performed on non-cancer cells, it is evident that cancer cells can also mount a senescence response. In this Review, we discuss how senescence can be induced in cancer cells. We describe the distinctive features of senescent cancer cells and how these changes in cellular physiology might be exploited for the selective eradication of these cells (senolysis). We discuss activation of the host immune system as a particularly attractive way to clear senescent cancer cells. Finally, we consider the challenges and opportunities provided by a ‘one-two punch’ sequential treatment of cancer with pro-senescence therapy followed by senolytic therapy.